Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Arovella Therapeutics Limited ( (AU:ALA) ) is now available.
Arovella Therapeutics announced the retirement of Dr. Thomas Duthy as Non-Executive Director and Chairman, effective July 1, 2025. Dr. Elizabeth Stoner will serve as interim Chair while the company seeks a permanent replacement. This leadership change occurs as Arovella prepares to advance its lead CAR-iNKT cell therapy program, ALA-101, into phase 1 clinical trials, marking a significant step in its strategic development and potential impact on cancer treatment.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company specializing in the development of invariant Natural Killer T (iNKT) cell therapy platforms aimed at treating blood cancers and solid tumors. Their lead product, ALA-101, involves CAR19-iNKT cells designed to target CD19, an antigen present on various cancer types. The company is also advancing its solid tumor treatment capabilities through technology licensed from Sparx Group.
Average Trading Volume: 2,186,150
Technical Sentiment Signal: Sell
Current Market Cap: A$130.4M
For a thorough assessment of ALA stock, go to TipRanks’ Stock Analysis page.